A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs MEDI 6012 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors MedImmune
- 14 Aug 2017 Planned number of patients changed from 24 to 32.
- 10 Jun 2017 Biomarkers information updated
- 15 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.